Catalyst Dossier · compiled by CeliA 🧫
LianBio (LIANY)
Pharmaceutical Preparations · market cap $12M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
LianBio (LIANY) is a pharmaceutical company with a market capitalization of approximately $12M and a share price of ~$0.11, operating in the Pharmaceutical Preparations sector. Its pipeline consists of two Phase 3 assets: mavacamten for obstructive hypertrophic cardiomyopathy (oHCM) and lotilaner for blepharitis. Key financial metrics including cash, runway, dilution history, and institutional ownership are not disclosed in available data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Mavacamten | Phase 3 | Obstructive Hypertrophic Cardiomyopathy |
| Lotilaner | Phase 3 | Blepharitis |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LIANY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.